The sensor to participate in the 2nd Annual LifeSci Partners Genetics Symposium on June 29, 2022

Montpellier, France, June 24, 2022– (work wire) – Regulatory information:

Sensors (FR0012596468 – ALSEN) (Paris:ALSEN) A number one clinical-stage biotechnology firm that makes a speciality of creating novel therapies for the restoration, remedy, and prevention of listening to loss problems, is happy to announce the participation of Nawal Ozern, CEO of LifeSci Companions 2.second abbreviation The Annual Symposium on Genetic Medicines takes place roughly 28-29 June 2022.

CEO Nawal Ozren will share a chat with Jeff Goodenburg as a part of LifeSci Companions 2second abbreviation Annual Symposium on Genetic Medicineson June 29, 2022. To attend the dialogue, please register over right here. A replay of the facet chat might be obtainable shortly after the presentation ends on the identical time Hyperlink.

Date: Wednesday 29 June 2022
subsequent to the hearth chat: 8.30 a.m. – 9 a.m. EST (2.30 p.m. – 3 p.m. CST)
OccasionLifeSci 2 . Companionssecond abbreviation Annual Symposium on Genetic Medicines

About Sensor

Sensorion is a number one clinical-stage biotechnology firm that makes a speciality of creating new therapies to revive, deal with and forestall listening to loss problems, a major unmet international medical want.

Sensorion has constructed a novel analysis and growth know-how platform to broaden its understanding of the pathophysiology and pathogenesis of the internal ear, enabling it to pick out the very best targets and strategies for drug candidates. Her portfolio combines small molecule packages with a preclinical portfolio of internal ear genetic therapies.

Its medical part portfolio contains one Part II product: SENS-401 (Arazasetron) advancing in a deliberate Part II medical research of the idea of SENS-401 in cisplatin-induced ototoxicity (CIO) and with accomplice Cochlear Restricted, a research of SENS-401 in Sufferers scheduled for cochlear implantation.

Sensorion has entered right into a broad strategic collaboration with the Pasteur Institute specializing in the genetics of audiology. It comprises two gene remedy packages geared toward correcting single-gene genetic types of deafness together with deafness brought on by a mutation within the gene coding for Otoferlin, and listening to loss related to a mutation within the GJB2 gene to deal with essential listening to loss segments in adults and youngsters. The corporate can be working to determine biomarkers to enhance the prognosis of those underserved ailments.

www.sensorion.com

a poster: sensor
inside: FR0012596468
mnemonic: ALSEEN

disclaimer

This press launch comprises sure forward-looking statements concerning Sensorion and its enterprise. These forward-looking statements are based mostly on assumptions that Sensorion considers cheap. Nonetheless, there will be no assure that these forward-looking statements might be verified, that are topic to quite a few dangers, together with these set forth within the Full 12 months 2021 Monetary Report printed on April 28, 2022 obtainable on our web site and to creating financial situations. and the monetary markets and markets through which Sensorion operates. The forward-looking statements contained on this press launch are additionally topic to dangers that aren’t but recognized to Sensorion or not presently thought of by Sensorion. The incidence of all or a part of these dangers may trigger Sensorion’s precise outcomes, monetary situations, efficiency or achievements to be materially totally different from such forward-looking statements. This press launch and the knowledge it comprises don’t represent a proposal to promote or subscribe or a solicitation of a proposal to purchase or subscribe for the shares of Sensorion in any nation. Relaying this press launch in some international locations could represent a violation of native legal guidelines and laws. Any recipient of this press launch should inform themselves of and adjust to any such native restrictions.

View the supply model on businesswire.com: https://www.businesswire.com/information/house/20220623005695/ar/

Contacts

Investor Relations
Catherine Levo
Head of Investor Relations and Communication
+33 6 72 18 00 22
ir.contact@sensorion-pharma.com

Worldwide Media Relations
Consilium Strategic Communications
Mary Jane Elliott / Jessica Hodgson
+44 7739 788014
+44 7561 424788
Sensorion@consilium-comms.com